{ "run_id": "democritus_glp1_minimum_viable_run_001", "created_at_utc": "2026-06-07T20:02:43.493771+00:00", "mode": "odyssey_executes_kimi_admitted_democritus_minimum_viable_run", "query": "Find a few articles on GLP-1 weight-loss drugs and synthesize their joint support.", "plan_source": "", "minimum_viable_run": [ "source_scout", "claim_extractor", "causal_mapper" ], "source_manifest": { "manifest_id": "glp1_weight_loss_article_seed_001", "query": "Find a few articles on GLP-1 weight-loss drugs and synthesize their joint support.", "retrieval_boundary": "seeded_from_current_web_check_and_repo_candidate; no uncontrolled browsing inside Kimi call", "source_family": "democritus", "target_foundry": "causal_claims_foundry", "articles": [ { "article_id": "step1_semaglutide_nejm_2021", "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity", "venue": "New England Journal of Medicine", "year": 2021, "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183", "study_type": "randomized_controlled_trial", "population": "adults with overweight or obesity without diabetes", "intervention": "semaglutide 2.4 mg once weekly plus lifestyle intervention", "primary_claim": "Semaglutide produced substantially greater mean weight loss than placebo at 68 weeks.", "reported_effect": "mean body-weight change about -14.9% with semaglutide versus -2.4% with placebo", "limitations": [ "trial context", "lifestyle intervention co-administered", "population excludes diabetes" ] }, { "article_id": "surmount1_tirzepatide_nejm_2022", "title": "Tirzepatide Once Weekly for the Treatment of Obesity", "venue": "New England Journal of Medicine", "year": 2022, "url": "https://www.nejm.org/doi/abs/10.1056/NEJMoa2206038", "study_type": "randomized_controlled_trial", "population": "adults with obesity or overweight and at least one complication, excluding diabetes", "intervention": "tirzepatide 5 mg, 10 mg, or 15 mg once weekly", "primary_claim": "Tirzepatide produced large and sustained weight reductions over 72 weeks versus placebo.", "reported_effect": "about 16.0% to 22.5% mean weight reduction across tirzepatide doses", "limitations": [ "sponsor-run phase 3 trial", "longer-term maintenance requires separate evidence" ] }, { "article_id": "step5_semaglutide_natmed_2022", "title": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "venue": "Nature Medicine", "year": 2022, "url": "https://pubmed.ncbi.nlm.nih.gov/36216945/", "study_type": "randomized_controlled_trial", "population": "adults with obesity or overweight with weight-related comorbidity, without diabetes", "intervention": "semaglutide 2.4 mg once weekly plus behavioral intervention", "primary_claim": "Continued semaglutide treatment maintained substantial weight loss at 104 weeks.", "reported_effect": "77.1% achieved at least 5% weight loss with semaglutide versus 34.4% with placebo", "limitations": [ "304 participants", "majority female and white", "continued treatment setting" ] }, { "article_id": "select_semaglutide_nejm_2023", "title": "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes", "venue": "New England Journal of Medicine", "year": 2023, "url": "https://pubmed.ncbi.nlm.nih.gov/?term=37952131", "study_type": "cardiovascular_outcomes_trial", "population": "adults with overweight or obesity, established cardiovascular disease, and no diabetes", "intervention": "semaglutide 2.4 mg once weekly", "primary_claim": "Semaglutide reduced major adverse cardiovascular events in a high-risk overweight/obesity population.", "reported_effect": "cardiovascular risk reduction complements weight-loss evidence", "limitations": [ "secondary to cardiovascular-risk population", "not a pure weight-loss trial" ] }, { "article_id": "surmount4_tirzepatide_jama_2023", "title": "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity", "venue": "JAMA", "year": 2023, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/", "study_type": "randomized_withdrawal_trial", "population": "adults with obesity or overweight after tirzepatide lead-in, excluding diabetes", "intervention": "continued tirzepatide versus placebo withdrawal after open-label lead-in", "primary_claim": "Continued tirzepatide better maintained and extended weight reduction than withdrawal.", "reported_effect": "withdrawal led to substantial regain while continued treatment maintained benefit", "limitations": [ "withdrawal design", "all participants first received tirzepatide" ] } ], "democritus_contract": { "local_charts": [ "source_selection", "claim_extraction", "causal_mapping", "joint_support", "scylla_review" ], "promotion_rule": "promote only claims preserving article id, population, intervention, effect, qualifier, and limitation", "obstruction_policy": "quarantine unsupported extrapolation, missing drug qualifier, cross-drug overgeneralization, and maintenance claims without duration evidence" } }, "role_outputs": [ { "role_id": "source_scout", "status": "pass", "selected_articles": [ { "article_id": "step1_semaglutide_nejm_2021", "study_type": "randomized_controlled_trial", "intervention": "semaglutide 2.4 mg once weekly plus lifestyle intervention", "population": "adults with overweight or obesity without diabetes", "primary_claim": "Semaglutide produced substantially greater mean weight loss than placebo at 68 weeks.", "limitations": [ "trial context", "lifestyle intervention co-administered", "population excludes diabetes" ] }, { "article_id": "surmount1_tirzepatide_nejm_2022", "study_type": "randomized_controlled_trial", "intervention": "tirzepatide 5 mg, 10 mg, or 15 mg once weekly", "population": "adults with obesity or overweight and at least one complication, excluding diabetes", "primary_claim": "Tirzepatide produced large and sustained weight reductions over 72 weeks versus placebo.", "limitations": [ "sponsor-run phase 3 trial", "longer-term maintenance requires separate evidence" ] }, { "article_id": "step5_semaglutide_natmed_2022", "study_type": "randomized_controlled_trial", "intervention": "semaglutide 2.4 mg once weekly plus behavioral intervention", "population": "adults with obesity or overweight with weight-related comorbidity, without diabetes", "primary_claim": "Continued semaglutide treatment maintained substantial weight loss at 104 weeks.", "limitations": [ "304 participants", "majority female and white", "continued treatment setting" ] }, { "article_id": "select_semaglutide_nejm_2023", "study_type": "cardiovascular_outcomes_trial", "intervention": "semaglutide 2.4 mg once weekly", "population": "adults with overweight or obesity, established cardiovascular disease, and no diabetes", "primary_claim": "Semaglutide reduced major adverse cardiovascular events in a high-risk overweight/obesity population.", "limitations": [ "secondary to cardiovascular-risk population", "not a pure weight-loss trial" ] }, { "article_id": "surmount4_tirzepatide_jama_2023", "study_type": "randomized_withdrawal_trial", "intervention": "continued tirzepatide versus placebo withdrawal after open-label lead-in", "population": "adults with obesity or overweight after tirzepatide lead-in, excluding diabetes", "primary_claim": "Continued tirzepatide better maintained and extended weight reduction than withdrawal.", "limitations": [ "withdrawal design", "all participants first received tirzepatide" ] } ], "source_quality_notes": [ "Fixed manifest preserves RCT/outcomes-trial distinction.", "Each article includes limitations before claim extraction." ], "promoted_claims": [ { "claim_id": "glp1_source_manifest_ready", "claim": "The GLP-1 seed manifest is adequate for a bounded Democritus synthesis smoke test.", "anchors": [ "step1_semaglutide_nejm_2021", "surmount1_tirzepatide_nejm_2022", "step5_semaglutide_natmed_2022", "select_semaglutide_nejm_2023", "surmount4_tirzepatide_jama_2023" ] } ], "qualified_claims": [], "review_claims": [], "open_questions": [ "Should broader real-world evidence be admitted in a later run or kept separate?" ] }, { "role_id": "claim_extractor", "status": "pass", "claims": [ { "claim_id": "claim::step1_semaglutide_nejm_2021", "article_id": "step1_semaglutide_nejm_2021", "claim": "Semaglutide produced substantially greater mean weight loss than placebo at 68 weeks.", "grounds": "mean body-weight change about -14.9% with semaglutide versus -2.4% with placebo", "qualifiers": [ "trial context", "lifestyle intervention co-administered", "population excludes diabetes" ], "intervention": "semaglutide 2.4 mg once weekly plus lifestyle intervention", "population": "adults with overweight or obesity without diabetes" }, { "claim_id": "claim::surmount1_tirzepatide_nejm_2022", "article_id": "surmount1_tirzepatide_nejm_2022", "claim": "Tirzepatide produced large and sustained weight reductions over 72 weeks versus placebo.", "grounds": "about 16.0% to 22.5% mean weight reduction across tirzepatide doses", "qualifiers": [ "sponsor-run phase 3 trial", "longer-term maintenance requires separate evidence" ], "intervention": "tirzepatide 5 mg, 10 mg, or 15 mg once weekly", "population": "adults with obesity or overweight and at least one complication, excluding diabetes" }, { "claim_id": "claim::step5_semaglutide_natmed_2022", "article_id": "step5_semaglutide_natmed_2022", "claim": "Continued semaglutide treatment maintained substantial weight loss at 104 weeks.", "grounds": "77.1% achieved at least 5% weight loss with semaglutide versus 34.4% with placebo", "qualifiers": [ "304 participants", "majority female and white", "continued treatment setting" ], "intervention": "semaglutide 2.4 mg once weekly plus behavioral intervention", "population": "adults with obesity or overweight with weight-related comorbidity, without diabetes" }, { "claim_id": "claim::select_semaglutide_nejm_2023", "article_id": "select_semaglutide_nejm_2023", "claim": "Semaglutide reduced major adverse cardiovascular events in a high-risk overweight/obesity population.", "grounds": "cardiovascular risk reduction complements weight-loss evidence", "qualifiers": [ "secondary to cardiovascular-risk population", "not a pure weight-loss trial" ], "intervention": "semaglutide 2.4 mg once weekly", "population": "adults with overweight or obesity, established cardiovascular disease, and no diabetes" }, { "claim_id": "claim::surmount4_tirzepatide_jama_2023", "article_id": "surmount4_tirzepatide_jama_2023", "claim": "Continued tirzepatide better maintained and extended weight reduction than withdrawal.", "grounds": "withdrawal led to substantial regain while continued treatment maintained benefit", "qualifiers": [ "withdrawal design", "all participants first received tirzepatide" ], "intervention": "continued tirzepatide versus placebo withdrawal after open-label lead-in", "population": "adults with obesity or overweight after tirzepatide lead-in, excluding diabetes" } ], "grounds": [ "mean body-weight change about -14.9% with semaglutide versus -2.4% with placebo", "about 16.0% to 22.5% mean weight reduction across tirzepatide doses", "77.1% achieved at least 5% weight loss with semaglutide versus 34.4% with placebo", "cardiovascular risk reduction complements weight-loss evidence", "withdrawal led to substantial regain while continued treatment maintained benefit" ], "warrants": [ "Trial/outcomes evidence supports only scoped population and intervention claims." ], "qualifiers": [ "304 participants", "all participants first received tirzepatide", "continued treatment setting", "lifestyle intervention co-administered", "longer-term maintenance requires separate evidence", "majority female and white", "not a pure weight-loss trial", "population excludes diabetes", "secondary to cardiovascular-risk population", "sponsor-run phase 3 trial", "trial context", "withdrawal design" ], "promoted_claims": [ { "claim_id": "claim::step1_semaglutide_nejm_2021", "article_id": "step1_semaglutide_nejm_2021", "claim": "Semaglutide produced substantially greater mean weight loss than placebo at 68 weeks.", "grounds": "mean body-weight change about -14.9% with semaglutide versus -2.4% with placebo", "qualifiers": [ "trial context", "lifestyle intervention co-administered", "population excludes diabetes" ], "intervention": "semaglutide 2.4 mg once weekly plus lifestyle intervention", "population": "adults with overweight or obesity without diabetes" }, { "claim_id": "claim::surmount1_tirzepatide_nejm_2022", "article_id": "surmount1_tirzepatide_nejm_2022", "claim": "Tirzepatide produced large and sustained weight reductions over 72 weeks versus placebo.", "grounds": "about 16.0% to 22.5% mean weight reduction across tirzepatide doses", "qualifiers": [ "sponsor-run phase 3 trial", "longer-term maintenance requires separate evidence" ], "intervention": "tirzepatide 5 mg, 10 mg, or 15 mg once weekly", "population": "adults with obesity or overweight and at least one complication, excluding diabetes" }, { "claim_id": "claim::step5_semaglutide_natmed_2022", "article_id": "step5_semaglutide_natmed_2022", "claim": "Continued semaglutide treatment maintained substantial weight loss at 104 weeks.", "grounds": "77.1% achieved at least 5% weight loss with semaglutide versus 34.4% with placebo", "qualifiers": [ "304 participants", "majority female and white", "continued treatment setting" ], "intervention": "semaglutide 2.4 mg once weekly plus behavioral intervention", "population": "adults with obesity or overweight with weight-related comorbidity, without diabetes" }, { "claim_id": "claim::select_semaglutide_nejm_2023", "article_id": "select_semaglutide_nejm_2023", "claim": "Semaglutide reduced major adverse cardiovascular events in a high-risk overweight/obesity population.", "grounds": "cardiovascular risk reduction complements weight-loss evidence", "qualifiers": [ "secondary to cardiovascular-risk population", "not a pure weight-loss trial" ], "intervention": "semaglutide 2.4 mg once weekly", "population": "adults with overweight or obesity, established cardiovascular disease, and no diabetes" }, { "claim_id": "claim::surmount4_tirzepatide_jama_2023", "article_id": "surmount4_tirzepatide_jama_2023", "claim": "Continued tirzepatide better maintained and extended weight reduction than withdrawal.", "grounds": "withdrawal led to substantial regain while continued treatment maintained benefit", "qualifiers": [ "withdrawal design", "all participants first received tirzepatide" ], "intervention": "continued tirzepatide versus placebo withdrawal after open-label lead-in", "population": "adults with obesity or overweight after tirzepatide lead-in, excluding diabetes" } ], "qualified_claims": [], "review_claims": [], "open_questions": [ "Should maintenance and cardiovascular outcome claims be separated into different foundry cells?" ] }, { "role_id": "causal_mapper", "status": "qualified", "causal_edges": [ { "edge_id": "edge::step1_semaglutide_nejm_2021", "source_claim_id": "claim::step1_semaglutide_nejm_2021", "article_id": "step1_semaglutide_nejm_2021", "anchors": [ "step1_semaglutide_nejm_2021" ], "intervention": "semaglutide 2.4 mg once weekly plus lifestyle intervention", "outcome": "weight loss or cardiometabolic outcome", "scope": { "population": "adults with overweight or obesity without diabetes", "study_type": "randomized_controlled_trial", "limitations": [ "trial context", "lifestyle intervention co-administered", "population excludes diabetes" ] }, "status": "qualified" }, { "edge_id": "edge::surmount1_tirzepatide_nejm_2022", "source_claim_id": "claim::surmount1_tirzepatide_nejm_2022", "article_id": "surmount1_tirzepatide_nejm_2022", "anchors": [ "surmount1_tirzepatide_nejm_2022" ], "intervention": "tirzepatide 5 mg, 10 mg, or 15 mg once weekly", "outcome": "weight loss or cardiometabolic outcome", "scope": { "population": "adults with obesity or overweight and at least one complication, excluding diabetes", "study_type": "randomized_controlled_trial", "limitations": [ "sponsor-run phase 3 trial", "longer-term maintenance requires separate evidence" ] }, "status": "qualified" }, { "edge_id": "edge::step5_semaglutide_natmed_2022", "source_claim_id": "claim::step5_semaglutide_natmed_2022", "article_id": "step5_semaglutide_natmed_2022", "anchors": [ "step5_semaglutide_natmed_2022" ], "intervention": "semaglutide 2.4 mg once weekly plus behavioral intervention", "outcome": "weight loss or cardiometabolic outcome", "scope": { "population": "adults with obesity or overweight with weight-related comorbidity, without diabetes", "study_type": "randomized_controlled_trial", "limitations": [ "304 participants", "majority female and white", "continued treatment setting" ] }, "status": "qualified" }, { "edge_id": "edge::select_semaglutide_nejm_2023", "source_claim_id": "claim::select_semaglutide_nejm_2023", "article_id": "select_semaglutide_nejm_2023", "anchors": [ "select_semaglutide_nejm_2023" ], "intervention": "semaglutide 2.4 mg once weekly", "outcome": "weight loss or cardiometabolic outcome", "scope": { "population": "adults with overweight or obesity, established cardiovascular disease, and no diabetes", "study_type": "cardiovascular_outcomes_trial", "limitations": [ "secondary to cardiovascular-risk population", "not a pure weight-loss trial" ] }, "status": "qualified" }, { "edge_id": "edge::surmount4_tirzepatide_jama_2023", "source_claim_id": "claim::surmount4_tirzepatide_jama_2023", "article_id": "surmount4_tirzepatide_jama_2023", "anchors": [ "surmount4_tirzepatide_jama_2023" ], "intervention": "continued tirzepatide versus placebo withdrawal after open-label lead-in", "outcome": "weight loss or cardiometabolic outcome", "scope": { "population": "adults with obesity or overweight after tirzepatide lead-in, excluding diabetes", "study_type": "randomized_withdrawal_trial", "limitations": [ "withdrawal design", "all participants first received tirzepatide" ] }, "status": "qualified" } ], "restriction_obligations": [ "Do not generalize semaglutide findings to tirzepatide or oral semaglutide without article-specific evidence.", "Do not treat cardiovascular outcomes trials as pure weight-loss efficacy trials.", "Keep continuation/withdrawal evidence distinct from initial efficacy evidence." ], "promoted_claims": [], "qualified_claims": [ { "edge_id": "edge::step1_semaglutide_nejm_2021", "source_claim_id": "claim::step1_semaglutide_nejm_2021", "article_id": "step1_semaglutide_nejm_2021", "anchors": [ "step1_semaglutide_nejm_2021" ], "intervention": "semaglutide 2.4 mg once weekly plus lifestyle intervention", "outcome": "weight loss or cardiometabolic outcome", "scope": { "population": "adults with overweight or obesity without diabetes", "study_type": "randomized_controlled_trial", "limitations": [ "trial context", "lifestyle intervention co-administered", "population excludes diabetes" ] }, "status": "qualified" }, { "edge_id": "edge::surmount1_tirzepatide_nejm_2022", "source_claim_id": "claim::surmount1_tirzepatide_nejm_2022", "article_id": "surmount1_tirzepatide_nejm_2022", "anchors": [ "surmount1_tirzepatide_nejm_2022" ], "intervention": "tirzepatide 5 mg, 10 mg, or 15 mg once weekly", "outcome": "weight loss or cardiometabolic outcome", "scope": { "population": "adults with obesity or overweight and at least one complication, excluding diabetes", "study_type": "randomized_controlled_trial", "limitations": [ "sponsor-run phase 3 trial", "longer-term maintenance requires separate evidence" ] }, "status": "qualified" }, { "edge_id": "edge::step5_semaglutide_natmed_2022", "source_claim_id": "claim::step5_semaglutide_natmed_2022", "article_id": "step5_semaglutide_natmed_2022", "anchors": [ "step5_semaglutide_natmed_2022" ], "intervention": "semaglutide 2.4 mg once weekly plus behavioral intervention", "outcome": "weight loss or cardiometabolic outcome", "scope": { "population": "adults with obesity or overweight with weight-related comorbidity, without diabetes", "study_type": "randomized_controlled_trial", "limitations": [ "304 participants", "majority female and white", "continued treatment setting" ] }, "status": "qualified" }, { "edge_id": "edge::select_semaglutide_nejm_2023", "source_claim_id": "claim::select_semaglutide_nejm_2023", "article_id": "select_semaglutide_nejm_2023", "anchors": [ "select_semaglutide_nejm_2023" ], "intervention": "semaglutide 2.4 mg once weekly", "outcome": "weight loss or cardiometabolic outcome", "scope": { "population": "adults with overweight or obesity, established cardiovascular disease, and no diabetes", "study_type": "cardiovascular_outcomes_trial", "limitations": [ "secondary to cardiovascular-risk population", "not a pure weight-loss trial" ] }, "status": "qualified" }, { "edge_id": "edge::surmount4_tirzepatide_jama_2023", "source_claim_id": "claim::surmount4_tirzepatide_jama_2023", "article_id": "surmount4_tirzepatide_jama_2023", "anchors": [ "surmount4_tirzepatide_jama_2023" ], "intervention": "continued tirzepatide versus placebo withdrawal after open-label lead-in", "outcome": "weight loss or cardiometabolic outcome", "scope": { "population": "adults with obesity or overweight after tirzepatide lead-in, excluding diabetes", "study_type": "randomized_withdrawal_trial", "limitations": [ "withdrawal design", "all participants first received tirzepatide" ] }, "status": "qualified" } ], "review_claims": [], "open_questions": [ "Should causal edges encode dose and duration as first-class typed fields?" ] } ], "handoffs": [ { "from_role": "source_scout", "to_role": "claim_extractor", "handoff_artifacts": [ "selected_articles", "source_quality_notes" ], "present_artifacts": [ "selected_articles", "source_quality_notes" ], "compatibility_check": "preserve article ids and limitations", "status": "pass" }, { "from_role": "claim_extractor", "to_role": "causal_mapper", "handoff_artifacts": [ "claims", "grounds", "qualifiers" ], "present_artifacts": [ "claims", "grounds", "qualifiers" ], "compatibility_check": "preserve claim ids, grounds, and qualifiers", "status": "pass" } ], "audit": [ { "gate_id": "source_quality_gate", "status": "pass", "rationale": "The fixed source manifest preserves study metadata and limitations.", "corrections": [] }, { "gate_id": "claim_grounding_gate", "status": "pass", "rationale": "Promoted and qualified claims preserve article ids or article anchors.", "corrections": [] }, { "gate_id": "causal_scope_gate", "status": "qualified", "rationale": "Causal edges preserve population and limitations, but dose/duration should become typed fields before full promotion.", "corrections": [ "promote dose and duration into first-class causal edge fields" ] }, { "gate_id": "handoff_compatibility_gate", "status": "pass", "rationale": "Executed handoffs preserve required upstream artifacts.", "corrections": [] } ], "metrics": { "article_count": 5, "role_count": 3, "handoff_count": 2, "promoted_claim_count": 6, "qualified_claim_count": 5, "audit_pass_count": 3, "audit_qualified_count": 1, "audit_review_count": 0 }, "admission_decision": { "decision": "democritus_minimum_viable_run_admitted_with_scope_qualification", "passed_gates": [ "source_quality_gate", "claim_grounding_gate", "handoff_compatibility_gate" ], "qualified_gates": [ "causal_scope_gate" ], "review_gates": [], "next_action": "Add synthesis_auditor and scylla_writer after typing dose/duration on causal edges." }, "ticket_transformer": { "acronym": "TICKET", "expansion": "Topos Integration using Causal Kan Extension Transformers", "checks": [ "typed_manifest", "subobject_classifier", "restriction_maps", "gluing_audit", "j_closure", "promotion_gate" ], "categorical_routine": "Kan-extension-style admission from a request-local artifact slice into durable Odyssey foundry state", "label": "TICKET(democritus_prometheus_run)", "source_family": "democritus", "target_foundry": "causal_claims_foundry", "foundry_expression": "TICKET(democritus_prometheus_run) -> compose(scientific_challenge, evidence_argument, causal_structure) -> glue(extraction_drift_audit)", "fsql_surface": "FROM prometheus_runs SLICE BY family(\"democritus\") TICKET BY target_foundry", "obstruction_policy": "preserve drift, off-topic extraction, weak causal joins, and unsupported claims as obstructions" } }